KinaseMD 2.0: an updated database of kinase mutations and drug response
Nucleic Acids Research · 12.11.2026
DOI: 10.1093/nar/gkag1170 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 12.11.2026. Verfasst von Xiaojiang Hu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha 410011, China. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Excellent Youth Foundation of Hunan Scientific Committee, Natural Science Foundation of China, Science and Technology Innovation Program of Hunan province.
Abstract (Originalsprache)
Kinase mutations can alter activity, inhibitor response and downstream phosphorylation signaling, particularly within four resistance-associated substructures: gatekeeper, G-loop, αC-helix, and A-loop. KinaseMD 2.0 (http://modinfor.com/KinaseMD/) updates the kinase-centered database in three areas. Integrating source-curated annotations with Dr. Kinase predictions expanded substructure annotations from 1162 to 13 522 and kinase coverage from 388 to 547. Updated pharmacogenomic and signaling layers contain 422 244 drug-response measurements, 1614 candidate drug-resistance evidence records, and 359 600 predicted phosphorylation-network rewiring events. The new Kinase Perturbation Evidence Mapping (KPEM) workflow combines LLM-based literature extraction from an initial collection of over 480 000 publications with standardized processing of 30 public drug-treatment phosphoproteomic datasets. It provides 23 757 kinase-level records of literature-reported evidence and 53 029 phosphoproteomic records across 5124 drug/agent categories and 1598 disease contexts, distinguishing reported phosphorylation evidence from inferred kinase-associated signaling responses. By linking resistance-associated substructures, cancer mutations, drug response, and phosphorylation signaling, KinaseMD 2.0 supports studies of drug-resistance mechanisms and kinase-inhibitor design and development.
Autor:innen und Institutionen
- Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha 410011, China.
- Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital of Central South University, Changsha 410011, Hunan, China.
- Hunan Engineering Research Center of AI Medical Equipment, The Second Xiangya Hospital of Central South University, Changsha 410011, China.
- Key Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education, School of Basic Medical Sciences, Fuzhou 350122, China.
- Department of Bioinformatics, Fujian Key Laboratory of Medical Bioinformatics, School of Medical Technology and Engineering, Fujian Medical University, Fuzhou 350122, China.
ORCID-Profile: Xiaojiang Hu, Shaofeng Lin, Haodong Xu
Förderung
- Excellent Youth Foundation of Hunan Scientific Committee
- Natural Science Foundation of China
- Science and Technology Innovation Program of Hunan province
- Scientific Research Program of FuRong Laboratory
Zitieren
APA
Hu, X., Lin, S., Fu, S., Zeng, J., Xu, Z., Zheng, T., Wang, T., Liu, X., Huang, P., Li, Z., Liu, T., & Xu, H. (2026). KinaseMD 2.0: an updated database of kinase mutations and drug response. Nucleic Acids Research. https://doi.org/10.1093/nar/gkag1170
Vancouver
Hu X, Lin S, Fu S, Zeng J, Xu Z, Zheng T, et al. KinaseMD 2.0: an updated database of kinase mutations and drug response. Nucleic Acids Research. 2026. doi:10.1093/nar/gkag1170
BibTeX
@article{Hu2026,
author = {Hu, Xiaojiang and Lin, Shaofeng and Fu, Shiyang and Zeng, Jing and Xu, Zhenmu and Zheng, Tao and Wang, Tao and Liu, Xinyi and Huang, Peng and Li, Zhihong and Liu, Tang and Xu, Haodong},
title = {KinaseMD 2.0: an updated database of kinase mutations and drug response},
journal = {Nucleic Acids Research},
year = {2026},
doi = {10.1093/nar/gkag1170}
}
EUVIMED